Developing point-of-care CAR T manufacturing
European Pharmaceutical Review
DECEMBER 27, 2023
Bridging therapy has been shown to correlate with an inferior response to CAR T-cell therapy due to both progression of the chemotherapy-refractory malignant disease during the manufacturing period and increased toxicity. After this incident CAR-related toxicity scales and guidelines were established to prevent adverse reactions.
82 
Let's personalize your content